New hope for advanced liver cancer: experimental drug takes on standard therapy
NCT ID NCT07300488
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares a new drug, pracytarabine, to the standard drug regorafenib in 60 people with advanced liver cancer that has stopped responding to targeted therapy and immunotherapy. The goal is to see if pracytarabine can help patients live longer. Participants receive either drug by infusion or pill, and researchers track survival and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pracytarabine
- What this could lead to
- If it works, this could offer a new treatment option for people with advanced liver cancer who have run out of standard therapies.
- What could go wrong
- This is an early-to-mid-stage trial with only 60 participants, so results may not apply widely. The new drug may not work better or could have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nanjing Tianyinshan Hospital
Nanjing, Jiangsu, 211100, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A made-to-order DNA vaccine takes aim at liver cancer's return
- Simple blood test aims to catch liver cancer before It's too late
- Engineered virus takes on liver cancer when standard treatment fails
- Ultrasound vs. MRI: which spots hidden liver cancer better?
- Epigenetic drug may re-sensitize liver tumors to immunotherapy
- New hope for liver cancer patients who failed immunotherapy?